Click to zoom 
Click to zoom 1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb.
2. Yervoy® (ipilimumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb.
Esophageal Cancer
1L unresectable advanced/recurrent/metastatic ESCC1*
Esophageal Cancer
1L unresectable advanced/recurrent/metastatic ESCC1*
Fixed nivolumab dosing (Q3W)
Weight-based nivolumab dosing (Q2W)
*Nivolumab, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic ESCC whose tumors express PD-L1 (≥1).
1L, first-line; ESCC, esophageal squamous cell carcinoma; IV, intravenous; PD, progressive disease; PD-L1, programmed death ligand-1; QxW, every x weeks.